PMC9251371_01
The clinical manifestation of the patient's hair after tofacitinib treatment; at 8, 16, and 24 weeks, the hair has regrown gradually.
fimmu-13-904156-g001.jpg
PMC9251371_01_fimmu-13-904156-g001.jpg
f1
Skin examination showed hair loss in the scalp, eyebrows, beard, and the rest of his body ( Figure 1 ).
Time course of the treatment and changes in the Severity of Alopecia Tool (SALT) score, the Alopecia Areata Investigator Global Assessment (AA-IGA ), and the levels of peripheral blood cytokines.
fimmu-13-904156-g002.jpg
PMC9251371_01_fimmu-13-904156-g002.jpg
f2
Results showed that IL-6, IL-17, and IL12p70 increased, while IL-4, IL-10, IFN-gamma, and tumor necrosis factor-alpha (TNF-alpha) levels were within the normal range ( Figure 2 ). Twenty-four weeks after tofacitinib treatment, the SALT and AA-IGA  scores decreased significantly to zero ( Figure 2 ). IFN-gamma, TNF-alpha, IL12p70, Th2 cytokines IL-4, IL-6, IL-10, and Th17 cytokines IL-17. IFN-gamma was found to have increased 72 times compared with the baseline before tofacitinib treatment ( Figure 2 ). However, this value still decreased compared to the baseline ( Figure 2 ).